Medication info

Ostepose Injection (Ibandronate Sodium Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Hubist Pharma Co., Ltd.
Appearance
This injectable medication is a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe with an attached single-use needle.
Packaging
3ml x 1 vial
Approval status
Active

MFDS item code 201801955 · Notified 2018.05.09

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then on. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower or whose creatinine clearance is 30ml/min or higher. Because clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is below 30ml/min, use of this drug is not recommended. Older adults No dose adjustment is necessary.
Child administration
Efficacy and safety in children 18 years of age and younger have not been studied.

Ingredients

Manufacturer
Hubist Pharma Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used for the treatment of osteoporosis in postmenopausal women.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then on. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower or whose creatinine clearance is 30ml/min or higher. Because clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is below 30ml/min, use of this drug is not recommended. Older adults No dose adjustment is necessary.

Child administration

Efficacy and safety in children 18 years of age and younger have not been studied.

Precautions

This medication must be administered intravenously, and caution is required as administration into the artery or around the vein can cause tissue damage. It must not be used in patients with a history of allergic reactions to this drug or its components, or in patients with untreated hypocalcemia. Various side effects may occur, including gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, muscle pain, joint pain, headache, and rash. Some patients may experience flu-like symptoms such as fever, chills, fatigue, arthralgia, myalgia, which are generally transient and mild to moderate in severity. Osteonecrosis of the jaw may occur during treatment, so special caution is needed for cancer patients or those receiving dental treatments. Calcium and vitamin D intake must be sufficient before administration and during treatment; hypocalcemia or bone and mineral metabolism disorders must be adequately treated. Patients with poor renal function or taking medications that may affect the kidneys require regular check-ups and monitoring. During the administration of this drug, excessive dental treatment should be avoided, and oral hygiene should be well managed. This drug can rarely cause severe side effects such as ocular inflammation, severe allergic reactions, skin rashes, atypical fractures, so any unusual symptoms should be reported to medical staff immediately. Women who are pregnant or breastfeeding are advised not to use this drug, and safety and efficacy have not been established for children under 18 years of age. In cases of overdose, renal and liver damage may occur, necessitating careful monitoring and appropriate treatment. This drug should not be mixed with calcium-containing solutions or other intravenous medications and should be administered only as an intravenous injection. After use, the syringe and needle should not be reused and must be disposed of safely.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, atypical subtrochanteric and femoral diaphyseal fractures, atypical fractures of the ilium, dizziness, optic atrophy, lower motor neuron lesions, tremor, gastrointestinal disease unspecified, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urination disorders, hematuria, skin desquamation, sensory loss, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air, and it is safe to store at a temperature between 1 and 30 degrees Celsius. Proper storage at the correct temperature can maintain the drug's efficacy and stability.

Appearance and packaging

Appearance

This injectable medication is a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe with an attached single-use needle.

Package unit

3ml x 1 vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.